JP2024537136A5 - - Google Patents

Info

Publication number
JP2024537136A5
JP2024537136A5 JP2024520700A JP2024520700A JP2024537136A5 JP 2024537136 A5 JP2024537136 A5 JP 2024537136A5 JP 2024520700 A JP2024520700 A JP 2024520700A JP 2024520700 A JP2024520700 A JP 2024520700A JP 2024537136 A5 JP2024537136 A5 JP 2024537136A5
Authority
JP
Japan
Prior art keywords
inhibitor
pharmaceutical composition
kras
pan
erbb family
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024520700A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024537136A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/045621 external-priority patent/WO2023059596A1/en
Publication of JP2024537136A publication Critical patent/JP2024537136A/ja
Publication of JP2024537136A5 publication Critical patent/JP2024537136A5/ja
Pending legal-status Critical Current

Links

JP2024520700A 2021-10-05 2022-10-04 KRAS G12D阻害剤と汎ErbBファミリー阻害剤との併用療法 Pending JP2024537136A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163252534P 2021-10-05 2021-10-05
US63/252,534 2021-10-05
PCT/US2022/045621 WO2023059596A1 (en) 2021-10-05 2022-10-04 COMBINATION THERAPIES OF KRAS G12D INHIBITORS WITH Pan ErbB FAMILY INHIBITORS

Publications (2)

Publication Number Publication Date
JP2024537136A JP2024537136A (ja) 2024-10-10
JP2024537136A5 true JP2024537136A5 (enExample) 2025-10-10

Family

ID=85803674

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024520700A Pending JP2024537136A (ja) 2021-10-05 2022-10-04 KRAS G12D阻害剤と汎ErbBファミリー阻害剤との併用療法

Country Status (10)

Country Link
US (1) US20240408099A1 (enExample)
EP (1) EP4412717A4 (enExample)
JP (1) JP2024537136A (enExample)
KR (1) KR20240089340A (enExample)
CN (1) CN118369119A (enExample)
AU (1) AU2022359880A1 (enExample)
CA (1) CA3233567A1 (enExample)
IL (1) IL311835A (enExample)
MX (1) MX2024004216A (enExample)
WO (1) WO2023059596A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4436571A4 (en) * 2021-11-24 2025-10-15 Merck Sharp & Dohme Llc SMALL MOLECULE INHIBITORS OF KRAS MUTATIONAL PROTEINS
AU2024321817A1 (en) * 2023-08-08 2026-03-05 Quanta Therapeutics, Inc. Combination therapies with kras modulators
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250114339A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy comprising a kras g12d inhibitor and an egfr inhibitor
US20250114346A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent
WO2026060400A1 (en) * 2024-09-16 2026-03-19 Quanta Therapeutics, Inc. Combination therapies with kras modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013139423A1 (en) 2012-03-19 2013-09-26 Merck Patent Gmbh Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with other anti-tumor compounds
EA202190749A1 (ru) * 2018-09-10 2021-07-09 Мирати Терапьютикс, Инк. Способы комбинированной терапии
EP3908283A4 (en) 2019-01-10 2022-10-12 Mirati Therapeutics, Inc. KRAS G12C INHIBITORS
MX2022002465A (es) 2019-08-29 2022-05-19 Mirati Therapeutics Inc Inhibidores de kras g12d.
WO2021106231A1 (en) 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
TW202317589A (zh) * 2021-07-14 2023-05-01 美商尼坎醫療公司 作為kras抑制劑的伸烷基衍生物

Similar Documents

Publication Publication Date Title
JP2024537140A5 (enExample)
JP2024537136A5 (enExample)
JP2022548791A5 (enExample)
JP2025000632A5 (enExample)
JP2024537139A5 (enExample)
JP2025000629A5 (enExample)
JP2025000630A5 (enExample)
JP2024537137A5 (enExample)
FI3849537T3 (fi) Yhdistelmäterapioita
JP2024540839A5 (enExample)
JP2025512999A5 (enExample)
JP2022509724A5 (enExample)
JP2022548255A5 (enExample)
JP2022500381A5 (enExample)
JP2022500385A5 (enExample)
CN101850047B (zh) 一种治疗湿疹皮炎的中药组合物及其制剂
JP2023540809A5 (enExample)
Kojonazarov et al. Effects of multikinase inhibitors on pressure overload-induced right ventricular remodeling
JP2022535577A5 (enExample)
JP2022530866A5 (enExample)
CN104107299A (zh) 一种治疗痛经的中药混合物
IL311834A (en) Combinations of KRAS G12D inhibitors with PI3KA inhibitors and therapeutic methods
IL311863A (en) Combinations of KRAS G12D inhibitors and irinotecan and therapeutic methods
IL315645A (en) Combination therapies comprising a sos1 inhibitor and an egfr inhibitor
CN108969642B (zh) 一种治疗慢性前列腺炎的中药复方外用制剂及其制备工艺